Details for New Drug Application (NDA): 208401
✉ Email this page to a colleague
The generic ingredient in QBRELIS is lisinopril. There are twenty-one drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the lisinopril profile page.
Summary for 208401
Tradename: | QBRELIS |
Applicant: | Azurity |
Ingredient: | lisinopril |
Patents: | 9 |
Pharmacology for NDA: 208401
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for 208401
Suppliers and Packaging for NDA: 208401
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
QBRELIS | lisinopril | SOLUTION;ORAL | 208401 | NDA | Azurity Pharmaceuticals, Inc. | 52652-3001 | 52652-3001-1 | 150 mL in 1 BOTTLE (52652-3001-1) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
Approval Date: | Jul 29, 2016 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Nov 6, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | ACUTE MYOCARDIAL INFARCTION | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Nov 6, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF TREATING HYPERTENSION | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Nov 6, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF TREATMENT OF HEART FAILURE |
Complete Access Available with Subscription